Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring Src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells

Molecular and Cellular Biology

Volumn 35, Issue 1, 2015, Pages 41-51

  Guo, Huaijian ^a,b   Cruz Munoz, Mario Ernesto ^a,c   Wu, Ning ^a   Robbins, Michael ^d   Veillette, André ^a,b,e  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c Department of Human Communication   (Mexico)

^d BRISTOL MYERS SQUIBB   (United States)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD150 ANTIGEN; CD45 ANTIGEN; ELOTUZUMAB; PROTEIN P55; PROTEIN SH2; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; SIGNALING LYMPHOCYTIC ACTIVATION MOLECULE F7; UNCLASSIFIED DRUG; IMMUNOGLOBULIN RECEPTOR; INOSITOL-POLYPHOSPHATE 5-PHOSPHATASE; MONOCLONAL ANTIBODY; PHOSPHATASE; PTPRC PROTEIN, HUMAN; SLAMF7 PROTEIN, HUMAN; TYROSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; COUPLING FACTOR; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME MECHANISM; EVALUATION STUDY; FEMALE; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOPRECIPITATION; MOUSE; MULTIPLE MYELOMA CELL LINE; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; ANIMAL; C57BL MOUSE; CHEMISTRY; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; CYTOLOGY; EXPERIMENTAL MELANOMA; GENE EXPRESSION REGULATION; HELA CELL LINE; METABOLISM; MULTIPLE MYELOMA; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD45; CERCOPITHECUS AETHIOPS; COS CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; KILLER CELLS, NATURAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MULTIPLE MYELOMA; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, IMMUNOLOGIC; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TYROSINE;

EID: 84920019769     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01107-14     Document Type: Article

References (47)

1. Veillette A, Guo H. 2013. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol Hematol 88:168-177. http://dx.doi.org/10.1016/j.critrevonc.2013.04.003.
2. Bouchon A, Cella M, Grierson HL, Cohen JI, Colonna M. 2001. Activation ofNKcell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family. J Immunol 167:5517-5521. http://dx.doi.org/10.4049/jimmunol.167.10.5517.
3. Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y, Rice AG, van Abbema A, Wong M, Liu G, Zhan F, Dillon M, Chen S, Rhodes S, Fuh F, Tsurushita N, Kumar S, Vexler V, Shaughnessy JD, Jr, Barlogie B, van Rhee F, Hussein M, Afar DE, Williams MB. 2008. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 14:2775-2784. http://dx.doi.org/10.1158/1078-0432.CCR-07-4246.
4. Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG, van Abbema A, Jesaitis L, Caras I, Law D, Weller E, Xie W, Richardson P, Munshi NC, Mathiot C, Avet-Loiseau H, Afar DE, Anderson KC. 2008. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibodydependent cellular cytotoxicity in the bone marrow milieu. Blood 112: 1329-1337. http://dx.doi.org/10.1182/blood-2007-08-107292.
5. Cruz-Munoz ME, Dong Z, Shi X, Zhang S, Veillette A. 2009. Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function. Nat Immunol 10:297-305. http://dx.doi.org/10.1038/ni.1693.
6. Tassi I, Colonna M. 2005. The cytotoxicity receptor CRACC (CS-1) recruits EAT-2 and activates the PI3K and phospholipase Cgamma signaling pathways in human NK cells. J Immunol 175:7996-8002. http://dx.doi.org/10.4049/jimmunol.175.12.7996.
7. ++ and Erk, leading to granule polarization. J Exp Med 211:727-742. http://dx.doi.org/10.1084/jem.20132038.
8. van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R, Balasa B, Ganguly B, Chao D, Rice AG, Zhan F, Shaughnessy JD, Jr, Barlogie B, Yaccoby S, Afar DE. 2009. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther 8:2616-2624. http://dx.doi.org/10.1158/1535-7163.MCT-09-0483.
9. Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, Fry J, Afar DE, Singhal AK. 2012. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 120:552-559. http://dx.doi.org/10.1182/blood-2011-06-360552.
10. Jakubowiak AJ, Benson DM, Bensinger W, Siegel DS, Zimmerman TM, Mohrbacher A, Richardson PG, Afar DE, Singhal AK, Anderson KC. 2012. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol 30:1960-1965. http://dx.doi.org/10.1200/JCO.2011.37.7069.
11. Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, Kaufman JL, Leleu X, Tsao LC, Westland C, Singhal AK, Jagannath S. 2012. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 30: 1953-1959. http://dx.doi.org/10.1200/JCO.2011.37.2649.
12. Lonial S, Kaufman J, Laubach J, Richardson P. 2013. Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma. Expert Opin Biol Ther 13:1731-1740. http://dx.doi.org/10.1517/14712598.2013.847919.
13. Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, Starling GC, Ciarlariello D, Bhaskar S, Briercheck EL, Hughes T, Yu J, Rice A, Benson DM, Jr. 2013. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother 62:1841-1849. http://dx.doi.org/10.1007/s00262-013-1493-8.
14. Roncagalli R, Taylor JE, Zhang S, Shi X, Chen R, Cruz-Munoz ME, Yin L, Latour S, Veillette A. 2005. Negative regulation of natural killer cell function by EAT-2, a SAP-related adaptor. Nat Immunol 6:1002-1010. http://dx.doi.org/10.1038/ni1242.
15. Dong Z, Davidson D, Perez-Quintero LA, Kurosaki T, Swat W, Veillette A. 2012. The adaptor SAP controls NK cell activation by regulating the enzymes Vav-1 and SHIP-1 and by enhancing conjugates with target cells. Immunity 36:974-985. http://dx.doi.org/10.1016/j.immuni.2012.03.023.
16. Weber M, Treanor B, Depoil D, Shinohara H, Harwood NE, Hikida M, Kurosaki T, Batista FD. 2008. Phospholipase C-gamma2 and Vav cooperate within signaling microclusters to propagate B cell spreading in response to membrane-bound antigen. J Exp Med 205:853-868. http://dx.doi.org/10.1084/jem.20072619.
17. Dong Z, Cruz-Munoz ME, Zhong MC, Chen R, Latour S, Veillette A. 2009. Essential function for SAP family adaptors in the surveillance of hematopoietic cells by natural killer cells. Nat Immunol 10:973-980. http://dx.doi.org/10.1038/ni.1763.
18. Desai DM, Sap J, Schlessinger J, Weiss A. 1993. Ligand-mediated negative regulation of a chimeric transmembrane receptor tyrosine phosphatase. Cell 73:541-554. http://dx.doi.org/10.1016/0092-8674(93)90141-C.
19. Latour S, Fournel M, Veillette A. 1997. Regulation of T-cell antigen receptor signalling by Syk tyrosine protein kinase. Mol Cell Biol 17:4434-4441.
20. Fuchs A, Cella M, Giurisato E, Shaw AS, Colonna M. 2004. Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). J Immunol 172:3994-3998. http://dx.doi.org/10.4049/jimmunol.172.7.3994.
21. Veillette A, Bookman MA, Horak EM, Bolen JB. 1988. The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosineprotein kinase p56lck. Cell 55:301-308. http://dx.doi.org/10.1016/0092-8674(88)90053-0.
22. Lee JK, Boles KS, Mathew PA. 2004. Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs. Eur J Immunol 34:2791-2799. http://dx.doi.org/10.1002/eji.200424917.
23. Veillette, A. 2010. SLAM-family receptors: immune regulators with or without SAP-family adaptors. Cold Spring Harb Perspect Biol 2:a002469. http://dx.doi.org/10.1101/cshperspect.a002469.
24. Cannons JL, Tangye SG, Schwartzberg PL. 2011. SLAM family receptors and SAP adaptors in immunity. Annu Rev Immunol 29:665-705. http://dx.doi.org/10.1146/annurev-immunol-030409-101302.
25. Veillette A, Latour S. 2003. The SLAM family of immune-cell receptors. Curr Opin Immunol 15:277-285. http://dx.doi.org/10.1016/S0952-7915(03)00041-4.
26. Sayos J, Martin M, Chen A, Simarro M, Howie D, Morra M, Engel P, Terhorst C. 2001. Cell surface receptors Ly-9 and CD84 recruit the Xlinked lymphoproliferative disease gene product SAP. Blood 97:3867-3874. http://dx.doi.org/10.1182/blood. V97.12.3867.
27. Galandrini R, Tassi I, Mattia G, Lenti L, Piccoli M, Frati L, Santoni A. 2002. SH2-containing inositol phosphatase (SHIP-1) transiently translocates to raft domains and modulates CD16-mediated cytotoxicity in human NK cells. Blood 100:4581-4589. http://dx.doi.org/10.1182/blood -2002-04-1058.
28. Banh C, Miah SM, Kerr WG, Brossay L. 2012. Mouse natural killer cell development and maturation are differentially regulated by SHIP-1. Blood 120:4583-4590. http://dx.doi.org/10.1182/blood-2012-04-425009.
29. Kurosaki T. 1999. Genetic analysis of B cell antigen receptor signaling. Annu Rev Immunol 17:555-592. http://dx.doi.org/10.1146/annurev.immunol.17.1.555.
30. Lee JK, Mathew SO, Vaidya SV, Kumaresan PR, Mathew PA. 2007. CS1 (CRACC, CD319) induces proliferation and autocrine cytokine expression on human B lymphocytes. J Immunol 179:4672-4678. http://dx.doi.org/10.4049/jimmunol.179.7.4672.
31. Kim JR, Mathew SO, Patel RK, Pertusi RM, Mathew PA. 2010. Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus. Clin Exp Immunol 160:348-358. http://dx.doi.org/10.1111/j.1365-2249.2010.04116.x.
32. Shrivastava P, Katagiri T, Ogimoto M, Mizuno K, Yakura H. 2004. Dynamic regulation of Src-family kinases by CD45 in B cells. Blood 103: 1425-1432. http://dx.doi.org/10.1182/blood-2003-03-0716.
33. Zhu JW, Brdicka T, Katsumoto TR, Lin J, Weiss A. 2008. Structurally distinct phosphatases CD45 and CD148 both regulate B cell and macrophage immunoreceptor signaling. Immunity 28:183-196. http://dx.doi.org/10.1016/j.immuni.2007.11.024.
34. Rhee I, Veillette A. 2012. Protein tyrosine phosphatases in lymphocyte activation and autoimmunity. Nat Immunol 13:439-447. http://dx.doi.org/10.1038/ni.2246.
35. Hesslein DG, Takaki R, Hermiston ML, Weiss A, Lanier LL. 2006. Dysregulation of signaling pathways in CD45-deficientNKcells leads to differentially regulated cytotoxicity and cytokine production. Proc Natl Acad Sci USA103:7012-7017. http://dx.doi.org/10.1073/pnas.0601851103.
36. Martin SM, Mehta IK, Yokoyama WM, Thomas ML, Lorenz RG. 2001. Development of intestinal intraepithelial lymphocytes, NK cells, and NK 11 T cells in CD45-deficient mice. J Immunol 166:6066-6073. http://dx.doi.org/10.4049/jimmunol.166.10.6066.
37. Yamada H, Kishihara K, Kong YY, Nomoto K. 1996. Enhanced generation of NK cells with intact cytotoxic function in CD45 exon 6-deficient mice. J Immunol 157:1523-1528.
38. Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L, Capanni M, Umansky V, Paschen A, Sucker A, Pende D, Groh V, Biassoni R, Hoglund P, Kato M, Shibuya K, Schadendorf D, Anichini A, Ferrone S, Velardi A, Karre K, Shibuya A, Carbone E, Colucci F. 2009. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest 119:1251-1263. http://dx.doi.org/10.1172/JCI36022.
39. Gilfillan S, Chan CJ, Cella M, Haynes NM, Rapaport AS, Boles KS, Andrews DM, Smyth MJ, Colonna M. 2008. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 205:2965-2973. http://dx.doi.org/10.1084/jem.20081752.
40. Iguchi-Manaka A, Kai H, Yamashita Y, Shibata K, Tahara-Hanaoka S, Honda S, Yasui T, Kikutani H, Shibuya K, Shibuya A. 2008. Accelerated tumor growth in mice deficient in DNAM-1 receptor. J Exp Med 205: 2959-2964. http://dx.doi.org/10.1084/jem.20081611.
41. Kageyama R, Cannons JL, Zhao F, Yusuf I, Lao C, Locci M, Schwartzberg PL, Crotty S. 2012. The receptor Ly108 functions as a SAP adaptordependent on-offswitch for T cell help to B cells and NKT cell development. Immunity 36:986-1002. http://dx.doi.org/10.1016/j.immuni.2012.05.016.
42. Zhao F, Cannons JL, Dutta M, Griffiths GM, Schwartzberg PL. 2012. Positive and negative signaling through SLAM receptors regulate synapse organization and thresholds of cytolysis. Immunity 36:1003-1016. http://dx.doi.org/10.1016/j.immuni.2012.05.017.
43. Kumar S, Rajkumar SV, Kimlinger T, Greipp PR, Witzig TE. 2005. CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. Leukemia 19:1466-1470. http://dx.doi.org/10.1038/sj.leu.2403823.
44. Moreau P, Robillard N, Avet-Loiseau H, Pineau D, Morineau N, Milpied N, Harousseau JL, Bataille R. 2004. Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica 89:547-551.
45. Pellat-Deceunynck C, Bataille R. 2004. Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression. Blood Cells Mol Dis 32:293-301. http://dx.doi.org/10.1016/j.bcmd.2003.12.001.
46. + plasma cells enrich for human tumorigenic myeloma cells. Leukemia 26:2530-2537. http://dx.doi.org/10.1038/leu.2012.140.
47. Descamps G, Pellat-Deceunynck C, Szpak Y, Bataille R, Robillard N, Amiot M. 2004. The magnitude of Akt/phosphatidylinositol 3=-kinase proliferating signaling is related to CD45 expression in human myeloma cells. J Immunol 173:4953-4959. http://dx.doi.org/10.4049/jimmunol.173.8.4953.